Noetik
Noetik builds artificial intelligence models of tumours from huge sets of tissue images and molecular data, to predict which patients will respond to a cancer drug and to find new targets.
Overview
Noetik, founded in 2023 in South San Francisco, is an AI-native biotechnology company that has assembled one of the largest multimodal tumour datasets (spatial transcriptomics, proteomics, histology and genomics from patient samples) plus its Perturb-map in vivo functional genomics platform. On these it trains foundation models of the tumour microenvironment, including OCTO-VirtualCell, Celleporter and TARIO-2, which identifies likely responders to the checkpoint combination botensilimab plus balstilimab from routine pathology images (June 2026, following a 2025 biomarker collaboration with Agenus). Applications span trial enrichment, repositioning of clinical-stage drugs and novel target discovery. In January 2026 GSK licensed Noetik's foundation models in an anchor partnership reported at USD 50 million. Noetik raised a USD 14 million seed led by DCVC (2023) and a USD 40 million Series A (2024).
Funding
All startupsNotes
top- Series A lead investor not named on fetched pages (Business Wire release blocked). Investor names other than DCVC come from logos on the company homepage.
Pages like this
not linked directly; found by shared links- CompanyImmunai
Shares Single-cell & spatial profiling, AI-driven drug & target discovery.
- IdeaAn open model of every cancer cell state, built from perturbation atlases
Shares Pathology & radiology foundation models, Single-cell & spatial profiling.
- CompanyPathos AI
Shares Pathology & radiology foundation models, AI-driven drug & target discovery.
- InstitutionChan Zuckerberg Biohub
Shares Pathology & radiology foundation models, Single-cell & spatial profiling.
- IdeaAn open foundation model of the cancer cell trained on perturbation data
Shares Single-cell & spatial profiling, AI-driven drug & target discovery.
- TechnologyAI compute and model platforms for oncology
Shares Pathology & radiology foundation models, AI-driven drug & target discovery.
- TechnologySpatial-omics-guided treatment selection
Shares Pathology & radiology foundation models, Single-cell & spatial profiling.
- IdeaPool every immunotherapy trial's biomarker data into one commons
Shares Pathology & radiology foundation models, Single-cell & spatial profiling.